Dachaigh › Aillse Sgamhain Neo-chealla-beag › Oregon › Eugene
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Eugene, OR
Tha 13 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Eugene (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A’ fastadhÌre 3
- Oncology Associates Of Oregon, Pc, Eugene
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- Oncology Associates of Oregon PC, Eugene
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A’ fastadhÌre 3
- Oncology Associates of Oregon, P.C., Eugene
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
A’ fastadhÌre 1/2
- Oncology Associates of Oregon, P.C., Eugene
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A’ fastadhÌre 3
- Clinical Study Site, Eugene
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A’ fastadhÌre 2/3
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- USO - Oncology Associates of Oregon, Eugene
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A’ fastadhÌre 1
- USOR - Oncology Associates of Oregon, P.C, Eugene
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A’ fastadhÌre 2
- Williamette Valley Cancer Institute and Research Center, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A’ fastadhÌre 1
- Willamette Valley Cancer Institute and Research Center, Eugene
MYLUNG Consortium Part 3: Observational Study
A’ fastadhSgrùdadh amharc
- Willamette Valley Cancer Institute and Research Center, Eugene
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Eugene
- Cancer Ovarian9 sgrùdaidhean
- Ailse Endometrial8 sgrùdaidhean
- Aillse a' bhroilleach7 sgrùdaidhean
- Leukemia Lymphocytic Cronach6 sgrùdaidhean
- Myeloma iomaill6 sgrùdaidhean
- Ailse metastatach6 sgrùdaidhean
- Aillse (gach seòrsa)6 sgrùdaidhean
- Ailseachadh nan Sgamhan5 sgrùdaidhean
- Degeneration Macular5 sgrùdaidhean
- Cleachdadh Drog agus Eisimeil5 sgrùdaidhean
- Obesity4 sgrùdaidhean
- Ro-throm3 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.